Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1812)
Drug Name
BRS-640
Synonyms
BRADYKININ; BRS 640; Bradykinin (synthetic); Bradykinin acetate salt; Bradykinin, Lysyl; Callidin I; Kallidin 9; Kallidin I; L-Bradykinin; PRS 640; S8TIM42R2W; Synthetic bradykinin; 58-82-2; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; CHEBI:3165; CHEMBL406291; EINECS 200-398-8; L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-arginine; UNII-S8TIM42R2W
Indication Atherosclerosis [ICD11: BA80] Phase 1 [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 1060.2 Topological Polar Surface Area 419
Heavy Atom Count 76 Rotatable Bond Count 27
Hydrogen Bond Donor Count 12 Hydrogen Bond Acceptor Count 14
Cross-matching ID
PubChem CID
439201
PubChem SID
3600 ; 841468 ; 3139670 ; 7978810 ; 15090019 ; 36883455 ; 50112435 ; 50849217 ; 53789586 ; 91689969 ; 93581329 ; 103279772 ; 103980149 ; 104619886 ; 126525053 ; 134341811 ; 135651637 ; 137019791 ; 137255716 ; 137275542 ; 162220561 ; 164779222 ; 184605781 ; 198973777 ; 224949119 ; 229099223 ; 241108945 ; 241376207 ; 247680280 ; 249727084 ; 252156939
ChEBI ID
CHEBI:3165
CAS Number
58-82-2
TTD Drug ID
D0X0BI
Formula
C50H73N15O11
Canonical SMILES
C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O
InChI
1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
InChIKey
QXZGBUJJYSLZLT-FDISYFBBSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
BK1-5 DM003424 N. A. Unclear 1 [8]
BK1-7 DM003423 N. A. Unclear 1 [8]
BK4-9 DM003425 N. A. Unclear 1 [8]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR003871 BRS-640 BK1-7 Unclear ACE [8]
MR003872 BRS-640 BK1-5 Unclear ACE [8]
MR003873 BRS-640 BK4-9 Unclear XPNPEP1 [8]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Angiotensin-converting enzyme 2 (ACE2) DME0446 Homo sapiens
ACE2_HUMAN
3.4.17.23
[2]
Arginine carboxypeptidase (CPN1) DME0500 Homo sapiens
CBPN_HUMAN
3.4.17.3
[3]
Carboxypeptidase M (CPM) DME0563 Homo sapiens
CBPM_HUMAN
3.4.17.12
[4]
Cathepsin H (CTSH) DME0562 Homo sapiens
CATH_HUMAN
3.4.22.16
[5]
Cathepsin K (CTSK) DME0573 Homo sapiens
CATK_HUMAN
3.4.22.38
[6]
Dipeptidyl peptidase II (DPP7) DME0592 Homo sapiens
DPP2_HUMAN
3.4.14.2
[7]
Kininase II (ACE) DMEN102 Homo sapiens
ACE_HUMAN
3.4.15.1
[8]
PABA peptide hydrolase (MEP1B) DME0580 Homo sapiens
MEP1B_HUMAN
3.4.24.63
[9]
Prolyl endopeptidase (PREP) DME0574 Homo sapiens
PPCE_HUMAN
3.4.21.26
[10]
Soluble aminopeptidase P (sAmp) DME0501 Homo sapiens
XPP1_HUMAN
3.4.11.9
[11]
Soluble aminopeptidase P (sAmp) DME0501 Homo sapiens
XPP1_HUMAN
3.4.11.9
[8]
Thimet oligopeptidase (THOP1) DME0577 Homo sapiens
THOP1_HUMAN
3.4.24.15
[12]
⏷ Show the Full List of 12  DME(s)
Experimental Enzyme Kinetic Data of This Drug
DME Name DME Info Kinetic Data Uniprot ID REF
Arginine carboxypeptidase (CPN1) DME0500 Km = 0.0706 microM
CBPN_HUMAN
[3]
Soluble aminopeptidase P (sAmp) DME0501 Km = 0.101 microM
XPP1_HUMAN
[11]
References
1 ClinicalTrials.gov (NCT00868855) Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease.
2 Nunn's Applied Respiratory Physiology (Eighth Edition). Chapter 11 - Nonrespiratory Functions of the Lung.2017, Pages 203-214.e2
3 Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009 Jan 9;284(2):751-8.
4 Interactions between carboxypeptidase M and kinin B1 receptor in endothelial cells. Inflamm Res. 2019 Oct;68(10):845-855.
5 Human brain cathepsin H as a neuropeptide and bradykinin metabolizing enzyme. Peptides. 2003 Dec;24(12):1977-84.
6 A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int Immunopharmacol. 2010 Jan;10(1):134-9.
7 Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 1989 Apr;52(4):1284-93.
8 Bradykinin metabolism pathway in the rat pulmonary circulation
9 Human and mouse homo-oligomeric meprin A metalloendopeptidase: substrate and inhibitor specificities. Biol Chem. 2007 Nov;388(11):1163-72.
10 Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides. 2006 Dec;27(12):3363-9.
11 Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese(II)-dependent enzyme. Biochemistry. 2000 Dec 12;39(49):15121-8.
12 Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE). Epilepsia. 2014 May;55(5):754-62.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.